Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Integrated BioPharma Inc. INBP

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$43.9M
▼ 19.3% YoY
$-2.8M
▼ 451.7% YoY
$895,000
▼ 52.2% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Business Lines which includes the operations of (i) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services, (ii) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC and the holding entity of the Company and (iii) all other inactive subsidiaries of the Company. The Company’s customers are located primarily in the United States and Luxembourg. As of September 23, 2025, we had approximately 153 full time employees, including 117 who are members of the local unit of the Teamsters Union and are covered by a collective bargaining agreement which expires on August 31, 2026.

Written from the business description in INTEGRATED BIOPHARMA INC's annual report to the U.S. Securities and Exchange Commission, filed 23 September 2025. Every sentence was checked against that document before publication.

Growth

USD 43.9M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 43.9 · Net income -2.8
25.0M50.0M
201020132016201920222025
Compound annual growth
−4.7%
−7.1%
+0.4%
+0.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −7.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−6 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.2% · Net -6.5%
-2%-4%-6%
201020172025
ROE
FY2025 · ROE -15.0%
50%100%-5%-10%
201020172025
Three returns, three denominators.

Each USD of equity lost 15 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.9
2M3M-1M-2M
201020172025

Total assetsUSD 25.3M
EquityUSD 17.7M
CashUSD 4.5M
Current ratio3.00×

Equity funds 70% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
INBP, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.10.10.10.10.10.10.00.00.00.00.00.00.00.00.0
Operating income $B−0.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0
EBITDA $B−0.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0
Income tax $B0.00.00.00.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
Net income $B−0.00.00.0−0.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0
Free cash flow $B0.00.00.00.00.00.00.0−0.00.00.0−0.0−0.00.0−0.0−0.00.0
EPS, diluted $−0.090.030.000.000.120.250.130.060.020.100.050.020.010.00−0.13−0.11
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−15.04.10.6−0.223.378.6103.2—————————
Shares out B0.030.030.030.030.030.030.030.030.020.020.020.020.020.020.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 77 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image